The mycobacterial glycolipid glucose monomycolate induces a memory T cell response comparable to a model protein antigen and no B cell response upon experimental vaccination of cattle  by Nguyen, Thi Kim Anh et al.
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limpet haemocyanin (KLH) in cattle, a species which, unlike mice, expresses group 1 CD1, showed that
GMM was equally efﬁcient as KLH in generating T cell responses in blood, but not in the draining lymph
node. Also, KLH induced strong antibody responses whereas GMM did not. These data suggest that non-
overlapping T cell populations are targeted and demonstrate the potential of glycolipids as a special class
of subunit vaccine candidates.
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cell memory
. Introduction
It has been fully established that proteins, including haptenized
nd glycosylated proteins, are the main targets of the adaptive
mmune system. More recently, non-protein antigens, including
lycolipids, have been shown to be recognized by T cells in vitro.
nlike protein antigens, glycolipids are presented to T cells by the
D1 family of proteins. CD1d presents a limited set of glycolipids
o specialized T cells, invariant NKT cells. CD1a, CD1b, and CD1c
roteins, collectively called group 1 CD1 proteins, present a more
iverse set of lipids to T cells with T cell receptors (TCR) that
o not seem to be invariant or otherwise different from regular
cells. Interestingly, not all CD1 isoforms are present in all ani-
al species, which is illustrated by the fact that mice only express
D1d molecules, and no group 1 CD1 molecules. Guinea pigs, cat-
le, rabbits, pigs, dogs, and humans express at least one group 1
D1 molecule but the exact numbers and isoforms expressed vary
ubstantially [1–8].
Many of the known lipid-reactive human T cell lines and clones
re derived from individuals suffering from a mycobacterial infec-
ion, or have been derived in vitro by repeated stimulation of T cells
∗ Corresponding author. Tel.: +31 030 2534345; fax: +31 030 2533555.
E-mail address: i.vanrhijn@uu.nl (I. Van Rhijn).
264-410X © 2009 Elsevier Ltd.
oi:10.1016/j.vaccine.2009.05.078
Open access under CC BY license.fromhealthy donorswithmycobacterial extracts. This has led to the
identiﬁcation and characterization of a number of CD1-presented
mycobacterial antigens including mycolates [9–11], diacylglycerols
(LAM) [12], polyisoprenoid lipids [13], sulfotrehalose-containing
lipids [14] and lipopeptides [15]. Of note, all mycobacterial antigens
appear to be presented by group 1 CD1 (CD1a, CD1b, and CD1c). The
mechanism of immune activation by the mycobacterial glycolipid
glucose monomycolate (GMM) has been described in great detail
[11,16,17]. GMM is known to be presented to human T cells by CD1b.
The TCR of the human T cell line LDN5 recognizes GMMof different
mycobacterial species that only differ in their lipid tails. The co-
crystal of human CD1b with GMM shows that both acyl chains are
buried in the antigen binding groove, leaving the glucose moiety
exposed on the surface of the CD1 molecule available for recogni-
tion by the TCR, explaining why one TCR can recognize GMM from
different sources [18].
Using the CD1 system for vaccine development would have
the advantage that the molecules it presents are not subject to
rapid mutations, like certain antigenic viral proteins. Also, the CD1
system has very limited polymorphism [19], minimizing inter-
individual differences in the capacity to present a certain antigen
within an outbred population. In addition, CD1-restricted T cells
have been shown to be able to express molecules that are very
effective in ﬁghting mycobacterial infections [20–22]. Last, many
currently used diagnostic tests for mycobacterial infections make
use of mycobacterial puriﬁed protein derivative (PPD) or related
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rotein preparations. These tests turn positive upon vaccination
ith BCG or killed bacteria because of priming of T cells that recog-
ize proteins that are present in those vaccines and in the PPD. It is
nlikely that immunization with CD1-presented glycolipids inter-
eres with PPD-based diagnostic testing, which would be another
dvantage of potential lipid-based vaccines.
Even though it has been shown that CD1d-restricted NKT cells
upport the development of memory B cells, NKT cells themselves
xpress a natural memory phenotype cannot be primed in the
ense that immunization with a CD1d-presented antigen improves
he strength and the kinetics of subsequent challenges [23–25]. To
ddress the question whether group 1 CD1-restricted T cells can be
rimed, guinea pigs have been immunized with total lipid extract
f Mycobacterium tuberculosis [26,27], but no other species have
een studied so far. Total lipid extracts are likely to stimulate the
D1 system by several mechanisms, including TLR-mediated adju-
ant activity [28], in addition to providing cognate CD1 antigens
hat are directly presented to T cells. Using pure antigens with-
ut known adjuvant activity facilitates the analysis of the adaptive
mmune response and limits the inﬂuence of immune stimulation
ia mechanisms other than the TCR and/or BCR.
The aim of the current study was to determine whether immu-
ization with a pure mycobacterial glycolipid can prime the
daptive immune system and generate T cellmemory, andwhether
his interferes with the PPD-based diagnostic skin test for tuber-
ulosis. To address these questions, we immunized cattle with
he highly puriﬁed glycolipid glucose monomycolate (GMM) in
he synthetic adjuvant dimethyl dioctadecyl ammonium bromide
DDA). As a control immunogenweused the protein keyhole limpet
aemocyanin (KLH) in the same adjuvant. Cattle were chosen for
his experiment because cattle are the natural host of several
ycobacterial pathogens and therefore a target species for vaccine
evelopment. Infections with Mycobacterium bovis, causing bovine
uberculosis, and Mycobacterium avium ssp. paratuberculosis, the
ausative agent of Johne’s disease or bovine paratuberculosis, cause
ubstantial economic losses in the cattle industry [29]. Also, cat-
le express CD1b molecules [2], which present GMM to T cells
rom cattle suffering frommycobacterial infection (Van Rhijn et al.,
anuscript submitted).
. Materials and methods
.1. Bacteria and antigens
Mycobacterium phlei and Nocardia farcinica were grown in
H9 culture medium (Difco) supplemented with 10% glucose and
.5mg/ml Tween-80 (Sigma–Aldrich). Bacteria were spun down
nd washed once with distilled water. The wet pellets were
xtracted for 2h at room temperature in chloroform:methanol 1:2
nd 2:1 (v:v) consecutively. The total lipid extracts were dried in a
otating evaporator at room temperature and redissolved in pure
hloroform. For the preparation of GMM, the total lipid extracts
ere fractionated by loading on a silica solid phase extraction col-
mn (Supelco) and consecutive elutionwith three column volumes
f chloroform, followed by three column volumes of 15%, 30%, 40%,
0%, 60%, 70%, and 80% acetone in chloroform, and ﬁnallywith pure
cetone. Quantiﬁcation and overall analysis was done by thin layer
hromatography (TLC) using GMM standards that were analyzed
y nanoelectrospray ionization mass spectrometry (ThermoFinni-
an LCQ Advantage). After loading the lipids, the TLC plates were
esolved in chloroform:methanol:water 60:16:1.5 (v:v) anddried at
oom temperature. TLC plates were sprayed with 3% cupric acetate
n 8%phosphoric acid, dried and baked at 150 ◦C for 1h. The fraction
ontaining pure GMM was dried and redissolved in chloroform for
torage.27 (2009) 4818–4825 4819
KLH, concanavalin A (conA), and nervonic acid were obtained
from Sigma–Aldrich. Phosphatidylinositol, and phosphatidyl-
choline were from Avanti Lipids.
2.2. Animals and immunization
For this study twelve Holstein-Friesian, 2-week-old bull calves
were purchased fromdocumented tuberculosis free and paratuber-
culosis unsuspected dairy herds in The Netherlands. The bulls were
group housed and conventionally reared using milk replacer, con-
centrate and roughage. At the age of 3months, following a 10-week
pre-immunization period, seven animals were immunized subcu-
taneously with KLH in the left shoulder andwith GMM in the other
shoulder. Each dose contained either 100g GMM or 100g KLH
(Sigma–Aldrich) in 0.75ml PBS/5% BSA, and 0.75ml of a 20mg/ml
suspension of DDA (Sigma–Aldrich) in PBS. GMM was dried under
a stream of nitrogen to remove organic solvent and sonicated in
PBS/5% BSA. The remaining ﬁve animals received twodoses of adju-
vant only, containing the same components, except for KLH and
GMM. A second immunization was performed 1 month after the
primary immunization. Two of the GMM/KLH-immunized animals
were euthanized at the end of the experiment and their left and
right prescapular lymph nodes were collected. Experiments were
approved by the Animal Ethical Committee of the University of
Utrecht, The Netherlands (protocol numbers DEC 0409.0801 and
DEC 2007.II.06.152).
In order to compare humoral responses of animals suffering
from an infection with a GMM-producing bacterium and ani-
mals exposed to GMM by immunization, sera of animals suffering
from clinical paratuberculosis, caused by natural exposure to M.
avium paratuberculosis, were included in this study. Diagnosis of
MAP infection was performed using a faecal culture system [30]
at the National Veterinary Health Service, Deventer, The Nether-
lands.
2.3. T cell proliferation assays
T cell assays were performed from 6 weeks before the ﬁrst
immunization till 4.5 months after the second immunization.
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized blood by histopaque ﬁcoll (Sigma–Aldrich) and lymph
node cells were isolated by cutting the lymph nodes in small pieces
and passage through a cell strainer (BD Falcon). T cell proliferation
assays were performed in round bottom 96-well plates (200,000
cells/well). GMM was used in series of dilutions after drying under
a stream of nitrogen gas to remove organic solvent and sonicating
to be dissolved in T cell medium consisting of RPMI supplemented
with10%FCS (Hyclone), penicillin and streptomycin (Gibco), 20mM
HEPES (Gibco), and 4ml 1N NaOH. For antibody blocking assays,
20g/ml of the anti-human CD1b monoclonal antibody BCD1b.3
or the isotype control P3 was continuously present during the T
cell culture. Proliferation wasmeasured after culture for three days
in the presence of serial dilutions of KLH, GMM, or concanavalin A
(ConA) in a 37 ◦C, 5% CO2 humidiﬁed incubator, followed by a 7h
pulse of 1Ci of [3H]thymidine before cells were harvested and
counted for -emissions. Stimulation indices (SI) were calculated
by dividing the number of counts per minute obtained with the
optimal antigen dilution by the number obtained by incubation
with medium alone (Table 1).
2.4. Enzyme-linked immunosorbent assaysTo assess serological responses, blood was collected in vacu-
tainer tubes (BD), centrifuged, and the serum was collected and
stored at −20 ◦C. Antigen-speciﬁc immunoglobulins were mea-
sured using enzyme-linked immunosorbent assays (ELISA). Lipids
4820 T.K.A. Nguyen et al. / Vaccine 27 (2009) 4818–4825
Table 1
Proliferation data, expressed in counts per minute (CPM), that form the basis of the stimulation indices presented in Fig. 1.
Animal# Immunization Symbol in Fig. 1 CPM GMMa SD CPM KLH SD CPM medium SD CPM ConA SD
0041 M. phlei GMM/KLH  19,838 19,581 22,300 24,425 320 538 185,909 94,281
0472 M. phlei GMM/KLH  18,863 22,569 16,863 12,853 204 1120 167,182 83,289
2629 M. phlei GMM/KLH  4,233 1,411 2,687 1,588 278 289 205,727 43,388
3051 M. phlei GMM/KLH 2,660 2,542 2,665 2,301 357 359 240,182 55,587
4815 N. farcinica GMM/KLH  1,340 1,149 1,410 1,267 267 232 138,136 96,760
5083 M. phlei GMM/KLH  9,603 7,198 9,338 5,663 467 638 169,818 66,562
9596 M. phlei GMM/KLH  4,915 1,799 4,413 2,388 595 758 237,364 59,488
0177 Adjuvant only  451 419 599 425 197 186 171,545 75,306
3050 Adjuvant only  2,190 1,996 1,519 691 803 598 210,545 54,959
4014 Adjuvant only ♦ 668 376 2,206 784 290 256 244,273 73,157
6597 Adjuvant only © 2,605 2,497 1,913 816 725 630 199,636 43,058
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a Average of CPM obtained upon in vitro stimulation of PBMC with the same GM
djuvant only immunized animals.
ere dried under nitrogen to remove chloroform and sonicated
n methanol. Polysorb plates (Nunc, Denmark) were coated with
g/well N. farcinica GMM or control lipids (PI, PE, or nervonic
cid) and dried overnight at room temperature in a fume hood.
ostar high-binding 96-well plates (Corning)were used to coat KLH
0.1g/well) by overnight incubation at 4 ◦C. After blocking with
locking reagent (Roche) for 1h, 1:30 dilutions of serum in PBS,
r PBS only as a negative control, were added to the plates and
ncubated overnight at 4 ◦C. Plates coated with GMM were washed
ith washing buffer consisting of PBS containing/0.05% Tween-20
Sigma–Aldrich), and plates coated with KLH were washed with
ashing buffer consisting of PBS/0.25% Tween-20. Biotinylated
ouse anti-bovine IgG total (Sigma–Aldrich), diluted 1:50,000 in
locking reagent, was added and incubated for 1h, followed by
hree washes with washing buffer, and a 1-h incubation with
1:4000 dilution of avidine PO (Dako) in blocking reagent. For
sotype-speciﬁc, antigen-speciﬁc ELISA, unlabelled mouse anti-
ovine IgG1, IgG2, IgM, or IgA (Prionics), diluted 1:4000 in
locking reagentwere added after serum incubation and incubated
vernight at 4 ◦C, followedby threewasheswithwashingbuffer and
1-h incubation with polyclonal rabbit anti-mouse (1:2000) con-
ugated to HRP (Roche). After three washes with washing buffer
nd two with PBS, ABTS (Roche) was used to develop green colour
hich was measured spectrophotometrically at the wavelength of
05nm. OD values of the wells that were incubated without serum
ere subtracted from the values obtained with serum.
.5. Skin testing
A single intradermal comparative cervical tuberculin test was
onductedaccording to the regulations (EUdirective64/432/EEC)at
he end of the experiment, 4months after the last immunization. In
hort, 0.1mlbovine tuberculin (2000 IU)and0.1mlavian tuberculin
2000 IU) (Central Veterinary Institute, Lelystad, The Netherlands)
ere injected intradermally in theneckof each animal. At 72hpost-
njection the skin-fold thickness was measured and corrected for
kin-fold thickness measured at time of application. Animals are
onsidered to test positive for M. bovis if, after 72h, the increase in
kin thickness at the site of application of bovine tuberculin ismore
han 4mm larger than for avian PPD. If the reaction to bovine PPD is
etween 2 and 4mm greater than the reaction to avian PPD, this is
onsidered an indeterminate result. Animals showing differences
ess than 2mm are considered negative..6. Statistics
Following Levene’s test for homogeneity of variance, the post-
mmunization T cell proliferation data and the ELISA data of the two
reatment groupswere analyzedwith one-way analysis of variance4,491 3,007 526 764 203,636 54,397
at was used for immunization, or with M. phlei GMM for stimulation of PBMC of
(ANOVA) using SPSS 15.0 software. Differenceswith a P value <0.05
were considered signiﬁcant.
3. Results
3.1. Immunization with GMM is as efﬁcient in priming T cell
responses as a protein antigen
To study the efﬁciency of T cell priming upon immunization
with a glycolipid antigen as compared with a known immunogenic
model protein, cattle (n=7)were immunizedwithGMMandKLH in
DDA. To reduce theeffects of inter-individual differences,whilepre-
venting any possible interaction of the two antigens when mixed,
the animals received the two antigens separately, in the right and
the left shoulder, on the same day. Another group of animals (n=5)
of the sameageandsex,housed togetherwith theGMM/KLH immu-
nized group, was immunized with adjuvant only and served as a
control group. Before theﬁrst immunizationand from1week till 4.5
months after the second immunization, animals were tested every
other week for T cell reactivity against GMM and KLH. The GMM
speciﬁc proliferative T cell response that was detected in freshly
isolated PBMC after immunization with GMM/KLH was signiﬁ-
cantly higher than in adjuvant only immunized animals (P<0.001)
(Fig. 1A). A similar pattern was observed for KLH when GMM/KLH
immunized and adjuvant only immunized groups were compared
(Fig. 1B). Of note, the strength of the response against KLH and
against GMMwas comparable. Before immunization there were no
signiﬁcant differences between the groups (not shown).
In order to be able to assess whether a cross-reactive T cell
response to GMMwould develop, the animalswere not immunized
with an identical GMM preparation, but rather with GMM from M.
phlei (n=6) or N. farcinica (n=1), which differ in their mycolic acid
structure. The purity and the size of the GMM preparations was
conﬁrmed by TLC and mass spectrometry (Fig. 2). Cross-reactive T
cell responses, measured by using GMM from N. farcinica to stimu-
late T cells from animals that were immunized with M. phlei GMM
and vice versa, were clearly detected, though they were in gen-
eral slightly weaker than the response against the GMM that was
used for immunization (Fig. 1A). The restriction element for human
GMM-speciﬁcTcells isCD1b. Toconﬁrmwhether theGMM-speciﬁc
T cell response in cattle was restricted by bovine CD1b, we suc-
cessfully performedantibodyblocking assaysusing the anti-human
CD1b antibody BCD1b.3 that has been used for this purpose in the
humansystem,andwhich isknowntocross-reactwithbovineCD1b
[2] (Fig. 1C).
These results indicate that, similar to protein antigen, immu-
nization with GMM antigen raises a T cell response that can be
detected in PBMC and that GMM is recognized by T cells regardless
of the bacterial source of the GMM.
T.K.A. Nguyen et al. / Vaccine 27 (2009) 4818–4825 4821
Fig. 1. T cell responses against GMM and KLH, induced by immunization. (A) Freshly isolated PBMC of GMM/KLH-immunized animals and adjuvant only immunized animals
were stimulated with GMM extracted from N. farcinica and M. phlei. The cross-reactive T cell stimulation shown is measured by stimulating the T cells with the GMM that
was not used for immunization. (B) In the same assay, the T cell response against the protein antigen KLH was determined. The T cell stimulation index was calculated by
dividing the [3H]thymidine incorporation of the antigen-stimulated PBMCby the [3H]thymidine incorporation of PBMC cultured inmediumwithout lipids (Table 1) after a 8-h
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erformed post-immunization on one animal. Black symbols represent the GMM/K
C) PBMCs of a GMM/KLH-immunized animal were incubated with GMM or med
CD1b.3, or the isotype control P3. Bars represent the mean CPM of triplicate wells
.2. Immunization with GMM does not cause a positive
ntradermal skin test for bovine tuberculosis
Four months after the second set of GMM/KLH immunizations,
ll animals were subjected to the standard comparative intrader-
al skin test for bovine tuberculosis. Bovine and avian PPDs were
pplied intradermally and the difference in the increase in skin
hickness after 72h was calculated. In one out of seven GMM/KLH-
mmunized animals and one out of ﬁve adjuvant only immunized
nimals the increase in skin thickness at the bovine PPD application
ite was between 2 and 4mm larger than at the avian PPD appli-
ation site, qualifying them as indeterminate responders. All other
nimals were negative.
.3. Unlike KLH, immunization with GMM does not induce a
trong antibody response
Antibodies against GMM and KLH in serum were examined
y ELISA. Initial testing for antigen-speciﬁc total IgG showed that
MM/KLH-immunized animals had generated a strong response to
LH as compared to adjuvant only immunized animals (P<0.01)
Fig. 3A). The situation was different for anti-GMM responses:
MM/KLH-immunized animals as well as adjuvant only immu-
ized animals showed a very weak IgG response against GMM
nd the difference between groups was not signiﬁcant (P>0.05)
Fig. 3A). To obtain amore complete viewof the antibody responses,
LISAs for antigen speciﬁc IgG1, IgG2, IgM, and IgAwere performedmean stimulation index (±standard deviation) of eight independent experiments
munized animals and white symbols represent adjuvant only immunized animals.
nly in the presence of the cross-reactive anti-human CD1b monoclonal antibody
dard deviation).
separately. We detected weak anti-GMM responses of the IgM
and IgA isotype (Fig. 3B and C). The IgA response against GMM
was signiﬁcantly higher in GMM/KLH-immunized animals than in
adjuvant only immunized animals (P<0.05), whereas the differ-
ence in IgM response was not (P>0.05). Also, anti-KLH responses
of the IgM and IgA isotype were weak. The differences between
GMM/KLH immunized and adjuvant only immunized groups were
not statistically signiﬁcant (P>0.05 for both isotypes) (Fig. 3D and
E). High serological responses of the IgG1 and IgG2 isotype were
detected against KLH in the GMM/KLH immunized group (P<0.01
for both isotypes) (Fig. 3F and G). Because we did not detect any
anti-GMM IgG responses in any of the immunized animals, and
no positive control bovine sera with known anti-GMM reactiv-
ity were available, we included sera of animals suffering from
advanced paratuberculosis in the study. GMM is an immunodomi-
nant glycolipid antigen during paratuberculosis, a disease caused
by infection of cattle with M. avium paratuberculosis (Van Rhijn
et al., manuscript submitted). Interestingly, strong anti-GMM IgG1
and IgG2 responses were detected in sera from paratuberculosis
infected animals, but no increased IgM and IgA (Fig. 3H). No anti-
KLH antibody response of any of the isotypes could be detected in
these clinical paratuberculosis sera (Fig. 3I). To rule out the possibil-
ity that the anti-GMM response of the sera from paratuberculosis
infected animals was reﬂecting an antigen-independent false pos-
itive signal in the ELISA, we showed that the same sera showed no
response against the non-relevant lipids phospatidylinositol, phos-
phatidylcholine, and the long chain fatty acid nervonic acid when
4822 T.K.A. Nguyen et al. / Vaccine 27 (2009) 4818–4825
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lig. 2. TLC and mass spectrometric analysis of M. phlei and N. farcinica GMM. Ten m
hloroform:methanol:water (v:v), sprayed with 3% cupric acetate in 8% phosphoric a
. farcinica GMM; lane 3: M. phlei GMM standard; lane 4: puriﬁed M. phlei GMM. Po
ested in parallel with GMM (Fig. 3J). In addition, sera from ani-
als acutely infected with enteropathogenic Escherichia coli K88,
bacterium that does not produce GMM, did not show a response
gainst GMM (Fig. 3J).
.4. T cells responses against GMM were not detected in draining
ymph nodes, while KLH-speciﬁc responses were
Protein-speciﬁc T cells can readily be detected in lymph nodes,
here they can provide help to B cells, and they are usually highly
bundant in the lymph nodes that drain an area of immunization or
nfection. To assess whether this is also the case for CD1-presented
ipid antigen, the left and right prescapular lymph nodes that
rained the area of immunization of two GMM/KLH-immunized
nimals that were euthanized at the end of the experiment were
ollected and used for T cell proliferation assays. As expected, a
ery strong anti-KLH response was elicited in both lymph nodes.
he response in the left lymphnode,where the KLH immunizations
ere applied, was stronger than in the right lymph node. Interest-
ngly, no anti-GMMT cell response could be detected at all in any of
he lymph nodes (Fig. 4A). An experiment performed on the same
ay on PBMC from the same animals showed clear T cell responses
gainst KLH and GMM of comparable strength, though lower than
he KLH responses measured in lymph nodes (Fig. 4B).
. Discussion
Immunization of cattle with a pure glycolipid, GMM, as we
escribe here inducesmemory T cell responses butminor antibody
esponses. Because the GMM that we used was highly puriﬁed and
idnot containanydetectableprotein, theobservedTcell responses
gainst GMM are probably not caused by protein contaminations
resent in the GMMpreparations. This is supported by the fact that
cells from animals immunizedwith GMMof one bacterial species
ecognizedGMMfromadifferent bacterial species. So, even if a very
ow protein contamination would have been present in the GMMrams of GMM was applied to a silica TLC plate. The plate was developed in 60:16:2
ried, and baked for 1h at 140 ◦C. Lane 1: N. farcinica GMM standard; lane 2: puriﬁed
mode spectra were collected by electrospray ionization mass spectrometry.
preparation used for vaccination, the subsequent in vitro recogni-
tion of GMM puriﬁed from a different bacterial species cannot be
explained by a memory response against protein because even if
the preparations contain proteins, they cannot be identical because
they would be from different bacterial species.
Even though the anti-GMMT cell responsewas highly compara-
ble to the T cell response against the control protein KLH in strength
and duration, these cells are likely to perform different functions
in vivo. Unlike KLH-speciﬁc T cells, we showed that T cells that
respond to GMM were not detectable in lymph nodes, including
the lymph node draining the vaccination site, which is one possi-
ble explanation for the big differences in antibody response against
these antigens. Another explanation for this is that B cell help is
most efﬁcient when the B cell presents the antigen directly to the
T cell. In humans and cattle, GMM is presented by CD1b, which is
not expressed by B cells. Therefore, cognate B cell help, in the strict
sense that theB cell internalizes the antigen that is recognizedby its
B cell receptor and presents it directly to T cells, cannot take place in
the case of GMM. Recently, in an immunization experiment inmice,
using a haptenized, CD1d-binding-galactosyl ceramide analogue,
a normal, class-switched antibody response was generated [31]. In
this case, cognate B cell help was provided by NKT cells, which was
possible because B cells express CD1d. Taken together it seems that,
unlike CD1d-restrictedNKT cells, CD1b-restricted T cells elicited by
immunizationwith GMMare not capable to provide B cell help. The
published in vitro studies are consistent with our observations in
the sense that group 1 CD1-restricted T cells are less dependent
on fully mature DC with the B7 costimulatory molecules, such as
found in lymph nodes, for their activation [28,32] and they express
a unique set of effector molecules which is not characteristic for T
cells providing B cell help [20,21,33].The lackofdevelopmentof antibodiesagainstGMMupon immu-
nization is not due to the absence of a B cell repertoire for this
antigen becausewe have shown that sera of animals suffering from
an infection with M. avium paratuberculosis do contain antibodies
against GMM. A possible explanation for the generation of antibod-
T.K.A. Nguyen et al. / Vaccine 27 (2009) 4818–4825 4823
Fig. 3. Serological responses of GMM/KLH-immunized animals against GMM and KLH. (A) Sera of GMM/KLH-immunized animals and adjuvant only immunized animals
were tested for total IgG responses against KLH and GMM in an ELISA. (B and C) Anti-GMM IgM and IgA were determined using an isotype-speciﬁc ELISA. (D–G) The anti-KLH
serological response was studied in more detail by determining the individual IgM, IgA, IgG1 and IgG2 responses. Each dot in panel A–G represents the mean absorbance
(±standard deviation) of eight independently obtained sera post-immunization from one animal. (H and I) Sera of ﬁve animals suffering from advanced paratuberculosis
were tested for anti-GMM and anti-KLH antibody responses of the IgM, IgA, IgG1, and IgG2 isotype and compared with the values obtained from the GMM/KLH immunized
group and the adjuvant only immunized group. In panel H and I, the anti-GMM IgG1 and IgG2 data as well as the data from the animals suffering from paratuberculosis are
based on a single serum per animal; all other data are based on eight independently collected sera per animal. (J) IgG1 responses against GMM, phosphatidylinositol (PI),
phosphatidylcholine (PC), and nervonic acid, a C24:1 fatty acid, were determined in sera from ﬁve animals suffering from an E. coli K88 infection and ﬁve animals suffering
from advanced paratuberculosis by ELISA.
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mmunizations using cell suspensions from the left (KLH immunization side) and
esults shown here were obtained with material from one animal. Highly comparab
es during infection and not by immunization may be that during
nfection in vivo, fragments of bacterial cellwalls, that contain other
ompounds including a variety of proteins, may function like a
onjugate vaccine. Also, mycobacteria are known to possess strong
djuvant activity.
The question arises whether the lack of generation of an anti-
ody responsewill be amajor impediment for the use of glycolipids
s subunit vaccines. In the case of mycobacteria, it has been sug-
ested that anti-lipid antibodies may provide protection [34,35],
ut others doubt whether an antibody response provides any pro-
ection at all. It is generally accepted that a strong cellular immune
esponse is beneﬁcial for the host. For the protection against
ther infectious agents, antibodies are required. Antibodies against
omplex glycosylations can be generated by means of conjugate
accines, and it might be possible to accomplish the same for
lycolipids. Regardless of the question whether the generation of
ntibody responses against a glycolipid is possible and necessary,
t may be worth to use glycolipids in a single or chemically diverse
ulti-subunit vaccine because group 1 CD1-restricted T cells have
ome unique features that are not shared by T cells induced by
mmunization with a regular protein. Thus, a broader range of the
mmune system will be primed by including a glycolipid in a mix-
ure of antigens. Proteins are known to be able to induce Th1, Th2,
ytotoxic, and regulatory T cell responses, but it seems that gly-
olipids do not induce the same effector T cell populations. We
ave shown here that glycolipid-speciﬁc T cells do not support the
eneration of strong antibody responses and others have reported
hat the phenotype of lipid-speciﬁc cytotoxic T cell clones does
ot overlap with peptide-speciﬁc cytotoxic T cells [20,21]. Also, it
s possible that regulatory T cells can exclusively be found in the
eptide-speciﬁc, MHC class II-restricted T cell population, and if so,
mmunizationwith pure glycolipids opens a possibility to avoid the
timulation of regulatory T cells.
We have shown that immunization with GMM does not cause
he standard intradermal tuberculosis test in bovines to turn pos-
tive. This is likely due to the absence of lipids and glycolipids inproliferation assays were performed 4.5 months after the second set of GMM/KLH
(GMM immunization side) prescapular lymph nodes (A), and from PBMC (B). The
ults were obtained in a second animal (not shown).
puriﬁed protein derivative (PPD). If it appears in the future that
vaccines exclusively consisting of lipids and/or glycolipids provide
a reasonable level of protection against mycobacterial infectious
diseases, a major advantage of using them, instead of the currently
used vaccines based on attenuated mycobacteria, like M. bovis
BCG,which provides some protection against tuberculosis, or killed
mycobacteria, like the Gudair vaccine against bovine paratuber-
culosis, is that they do not cross-react with PPD-based diagnostic
tests.
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